Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 2013. The report details a specific share repurchase transaction executed on August 9, 2013, in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 610,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,669.00 pence; lowest price paid was 1,654.00 pence.
- Treasury Holdings (Settled): 506,610,412 shares (9.36% of total issued share capital).
- Treasury Holdings (Including Unsettled): 508,740,412 shares (10.37% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,906,123,368 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 610,000 shares for treasury. This transaction increased the percentage of total voting rights held in treasury from the prior settled position to 10.37% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in treasury (506,610,412 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (10.37% held in treasury including unsettled shares).
- Check the denominator for disclosure obligations under the Financial Conduct Authority's rules (4,906,123,368 shares in issue).
- Note that this filing does not contain operational or financial performance data for the period.